A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(14 sites)

United States

Stanford University Medical Center - Blake Wilbur Drive, Palo Alto, California

Yale University Hospital, New Haven, Connecticut

Norton Cancer Institute, Louisville, Kentucky

University of Maryland Greenebaum Cancer Center, Baltimore, Maryland

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Roswell Park Cancer Institute, Buffalo, New York

Atrium Health Levine Cancer Institute, Charlotte, North Carolina

The Ohio State University James Cancer Hospital, Columbus, Ohio

Penn Medicine University of Pennsylvania Health System, Philadelphia, Pennsylvania

Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Fox Chase Cancer Center, Philadelphia, Pennsylvania

MD Anderson Cancer Center, Houston, Texas